最新消息

News
漢康生技攜手高醫簽署合作備忘錄 深化癌症臨床研究合作 HanchorBio and Kaohsiung Medical University Hospital Sign MOU to Strengthen Cancer Clinical Research Collaboration
HanchorBio announced the signing of a Memorandum of Understanding (MOU) with Kaohsiung Medical University Hospital (KMUH). The collaboration combines HanchorBio's expertise in innovative drug development and clinical development with KMUH's clinical and research expertise in gastrointestinal oncology to explore potential opportunities for future clinical research. Both parties aim to generate additional scientific evidence in cancer research through clinical studies, while maintaining rigorous standards of patient safety, medical ethics, and regulatory compliance.
11 月 05, 2026
Read more
漢康生技攜手 Aston Sci 展開策略合作 結合癌症疫苗與次世代免疫療法,探索創新聯合治療潛力 HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
HanchorBio and Aston Sci today announced a strategic research collaboration to evaluate novel combination therapies joining HanchorBio's HCB101 macrophage-directed immunotherapy with Aston Sci's therapeutic cancer vaccine candidates.
10 月 22, 2026
Read more
漢康-KY將於5月29日創新板掛牌 HCB101臨床進展帶動國際合作布局 HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions
HanchorBio announced that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.
5 月 28, 2026
Read more
漢康-KY引進國際策略投資人奧博資本入股 5月29日創新板掛牌 詢圈超額認購 HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
HanchorBio announced the completion of bookbuilding for its initial public offering on the Taiwan Innovation Board. The offering price has been set at NT$120 per share. HanchorBio is expected to list on the Taiwan Innovation Board on May 29, 2026.
5 月 26, 2026
Read more
首筆授權金挹注營收 漢康-KY聚焦2026年臨床與商務發展重點 推進HCB101臨床開發、創新板上市進程及國際合作布局 HanchorBio Reports First Licensing Revenue and Outlines 2026 Clinical and Business Development Priorities
HanchorBio today announced that its 2026 Annual General Meeting was successfully held on May 21, 2026, in Taipei, Taiwan. Shareholders approved all proposed resolutions, including the 2025 business report, financial statements, and loss offset proposal.
5 月 21, 2026
Read more
HanchorBio-Taiwan-Innovation-Board-Listing
漢康-KY上市前業績發表會 5/11登場 FBDB核心平台構築抗癌護城河 瞄準千億美元商機 HanchorBio to Hold May 11 Investor Presentation Ahead of Planned Taiwan Innovation Board Listing
HanchorBio announced that it will hold an investor presentation on May 11 ahead of its planned listing on the Taiwan Innovation Board later this month.
5 月 08, 2026
Read more
HanchorBio-Selects-Bloomberg-to-Strengthen-its-Strategic-Intelligence-Across-Drug-Development-and-Global-Biopharma
漢康生技與彭博合作 強化藥物開發及全球生物製藥戰略情報能力 HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
HanchorBio announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.
4 月 24, 2026
Read more
HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering 漢康-KY獲證交所董事會通過股票創新板上市 核心技術FBDB™平台開發價值高
HanchorBio, Inc., a global clinical-stage biotechnology company advancing next-generation multifunctional biologics across oncology and immune-related diseases, today announced that it has received approval from the Board of Directors of the Taiwan Stock Exchange to list on the TWSE Innovation Board, with listing anticipated in the second quarter of 2026, subject to completion of the remaining customary procedures.
3 月 24, 2026
Read more
Strategic-Partnership-Between-Hanchorbio-and-WuXi-Biologics
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline漢康生技攜手藥明生物,推進新一代雙/多功能融合蛋白平臺及多專案產品線開發
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline. 致力於開發下一代免疫療法的全球臨床階段生物技術公司漢康生技與全球領先的CRDMO服務公司藥明生物共同宣佈,雙方簽署戰略合作協定,藥明生物將為漢康生技管線中多款新一代雙功能及多功能融合蛋白專案提供開發與生產服務。
1 月 26, 2026
Read more
HanchorBio-and-Henlius-Sign-Major-Licensing-Deal-for-HCB101-to-Expand-Global-Immuno-Oncology-Reach
漢康-KY完成抗癌藥HCB101授權簽署 推動癌症治療新標竿
專注於免疫腫瘤學創新生物藥開發的漢康-KY(7827)6月30日宣布,與上海復宏漢霖生物技術股份有限公司(以下 […]
6 月 30, 2025
Read more